CircRNA composition marker for identifying non-small cell lung cancer (NSCLC) subtypes and application of circRNA composition marker

Abstract

The invention discloses a circRNA composition marker for diagnosing and identifying non-small cell lung cancer (NSCLC) subtypes and application of the circRNA composition marker, including applicationof hsa_circ_0069841, hsa_circ_001357 and a combination of hsa_circ_001357 and hsa_circ_0069841 in identifying the NSCLC subtypes, and further provides a kit and gene chip prepared from a reagent fordetecting the hsa_circ_0069841, the hsa_circ_001357 and the combination of the hsa_circ_001357 and the hsa_circ_0069841. It is found that the hsa_circ_0069841 and the hsa_circ_001357 can have remarkable specificity and sensitivity to identification of lung adenocarcinoma and lung squamous cell carcinoma in the NSCLC independently or in a combined mode, the diagnosis speed is high, the cost is low,the result is accurate and reliable, rapid and accurate identification of lung cancer subtypes is facilitated through the prepared kit and gene chip, and a reliable basis is provided for targeted therapy of NSCLC patients.

Description

technical field [0001] The invention relates to the technical fields of medicine and clinical diagnosis, in particular to a circular RNA composition marker for identifying subtypes of non-small cell lung cancer and its application. Background technique [0002] Malignant tumors have become a major high-risk disease that seriously threatens human health. The morbidity and mortality of lung cancer rank first among all malignant tumors worldwide. Lung cancer is the most common cancer in my country, and it is the top priority of cancer prevention and treatment. At present, the incidence of lung cancer in my country is increasing by about 26% every year. If effective control measures are not taken in time, it is estimated that by 2025, the number of lung cancer patients in my country will reach 1 million, becoming the world's largest lung cancer country. [0003] Among lung cancers, non-small cell lung cancer (NSCLC) is the most common clinical pathological type of lung cancer,...

AI Technical Summary

Problems solved by technology

Limited by the lack of high-specificity and sensitivity early screening methods, about 75% of patients have local or distant metastases at the time of diagnosis. Due to the wide range of lesions, middle and advanced lung tumors are often difficult to be cured, and the 5-year survival rate is still insufficient 20%

[0006] In the prior art, the role of circular RNA in the diagnosis and treatment of lung cancer has also been proposed. For example, the Chinese patent No. 202010227453.3 "A Circular RNA and Its Application" shows that by changing the function of circular RNA circ_0058040 The expression has an impact on the proliferation, apoptosis and drug sensitivity of non-small cell lung cancer cells, indicating that reducing the expression of circular RNA circ_0058040 can inhibit the proliferation of non-small cell lung cancer cells and enhance their sensitivity to targeted drugs, but it does not explain which Gene enables accurate detection of lung cancer biomarkers

The patent number is CN202010654555.3 "a diagnostic kit for detecting NSCLC and its use and application", although the hsa_circ_0069841 gene is given as a biomarker for detecting NSCLC, but there is no way to distinguish the specific type of lung cancer. Specifically for NSCLC, squamous cell carcinoma and adenocarcinoma have completely different histological sources, cell growth speed, speed of metastasis, and treatment methods.

Therefore, for patients, there is still a lack of a fast and effective technical means to distinguish squamous cell carcinoma and adenocarcinoma, so that doctors can better formulate treatment plans

Images